{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:19:56Z","timestamp":1788941996025,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2025.100810","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:27:16Z","timestamp":1757860036000},"page":"100810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes"],"prefix":"10.1016","volume":"5","author":[{"given":"Sara","family":"Naimimohasses","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7765-8271","authenticated-orcid":false,"given":"Ankit","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bima J.","family":"Hasjim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gastha.2025.100810_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.gastha.2025.100810_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.gastha.2025.100810_bib3","series-title":"Cystic Fibrosis Foundation Patient Registry 2014 Annual data report","year":"2014"},{"issue":"6","key":"10.1016\/j.gastha.2025.100810_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jcf.2024.06.012","article-title":"Clinical outcomes after liver transplant in people with cystic fibrosis: a systematic review and meta-analysis","volume":"23","author":"Albaiz","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2025.100810_bib6","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jcf.2017.03.006","article-title":"Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension","volume":"16","author":"Witters","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.gastha.2025.100810_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.gastha.2025.100810_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/FPC.0000000000000246","article-title":"PharmGKB summary: ivacaftor pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"10.1016\/j.gastha.2025.100810_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","article-title":"Lumacaftor\/Ivacaftor: a review in cystic fibrosis","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.gastha.2025.100810_bib10","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther JPPT Off J PPAG"},{"issue":"19","key":"10.1016\/j.gastha.2025.100810_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gastha.2025.100810_bib12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.gastha.2025.100810_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/LVT.0000000000000529","article-title":"Have CFTR modulators changed the need for liver and lung transplantation among patients with cystic fibrosis? An analysis of the UNOS database","volume":"31","author":"Mendizabal","year":"2025","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.gastha.2025.100810_bib14","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/ppul.26396","article-title":"Use of CFTR modulators in special populations, part 3: solid organ transplant","volume":"58","author":"Kadouh","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"10212","key":"10.1016\/j.gastha.2025.100810_bib15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"1","key":"10.1016\/j.gastha.2025.100810_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2023.04.023","article-title":"Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and liver transplant","volume":"23","author":"Tachtatzis","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib19","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.02.006","article-title":"Effects of CFTR modulator therapies on liver stiffness and bile flow: a single-centre experience","volume":"79","author":"Calvo","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcf.2023.09.006","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","volume":"23","author":"Tewkesbury","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4254\/wjh.v14.i2.411","article-title":"Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis","volume":"14","author":"Ramsey","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.gastha.2025.100810_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatol Baltim Md"},{"issue":"2","key":"10.1016\/j.gastha.2025.100810_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2025.100810_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/j.2040-4603.2013.tb00495.x","article-title":"Physiology of cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr Physiol"},{"issue":"1","key":"10.1016\/j.gastha.2025.100810_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jcf.2024.09.015","article-title":"Linkage of the CF foundation patient registry with the scientific registry of transplant recipients database","volume":"24","author":"Cromwell","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.gastha.2025.100810_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:10:53Z","timestamp":1770685853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572325001979"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100810","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100810"}}